Chongqing Zhifei Bio Products (300122) - Total Assets
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) holds total assets worth CN¥29.09 Billion CNY (≈ $4.26 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chongqing Zhifei Bio Products - Total Assets Trend (2007–2025)
This chart illustrates how Chongqing Zhifei Bio Products's total assets have evolved over time, based on quarterly financial data. Also see 300122 market cap overview for the company's overall valuation and market capitalisation.
Chongqing Zhifei Bio Products - Asset Composition Analysis
Current Asset Composition (December 2025)
Chongqing Zhifei Bio Products's total assets of CN¥29.09 Billion consist of 60.0% current assets and 40.0% non-current assets. Review debt load of Chongqing Zhifei Bio Products to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.3% |
| Accounts Receivable | CN¥11.16 Billion | 35.2% |
| Inventory | CN¥5.00 Billion | 15.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.58 Billion | 8.1% |
| Goodwill | CN¥19.28 Million | 0.1% |
Asset Composition Trend (2007–2025)
This chart illustrates how Chongqing Zhifei Bio Products's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 300122 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chongqing Zhifei Bio Products's current assets represent 60.0% of total assets in 2025, a decrease from 86.1% in 2007.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2025, down from 41.4% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 1.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 35.2% of total assets.
Chongqing Zhifei Bio Products Competitors by Total Assets
Key competitors of Chongqing Zhifei Bio Products based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Chongqing Zhifei Bio Products - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.14 | 2.30 | 1.89 |
| Quick Ratio | 2.46 | 1.03 | 1.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥11.19 Billion | CN¥22.41 Billion | CN¥8.85 Billion |
Chongqing Zhifei Bio Products - Advanced Valuation Insights
This section examines the relationship between Chongqing Zhifei Bio Products's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.07 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -36.4% |
| Total Assets | CN¥31.72 Billion |
| Market Capitalization | $4.28 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Chongqing Zhifei Bio Products's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Chongqing Zhifei Bio Products's assets decreased by 36.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Chongqing Zhifei Bio Products (2007–2025)
The table below shows the annual total assets of Chongqing Zhifei Bio Products from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥31.72 Billion ≈ $4.64 Billion |
-36.45% |
| 2024-12-31 | CN¥49.91 Billion ≈ $7.30 Billion |
-0.64% |
| 2023-12-31 | CN¥50.23 Billion ≈ $7.35 Billion |
+32.18% |
| 2022-12-31 | CN¥38.00 Billion ≈ $5.56 Billion |
+26.48% |
| 2021-12-31 | CN¥30.05 Billion ≈ $4.40 Billion |
+97.42% |
| 2020-12-31 | CN¥15.22 Billion ≈ $2.23 Billion |
+39.09% |
| 2019-12-31 | CN¥10.94 Billion ≈ $1.60 Billion |
+60.68% |
| 2018-12-31 | CN¥6.81 Billion ≈ $996.54 Million |
+65.86% |
| 2017-12-31 | CN¥4.11 Billion ≈ $600.82 Million |
+51.54% |
| 2016-12-31 | CN¥2.71 Billion ≈ $396.48 Million |
+1.04% |
| 2015-12-31 | CN¥2.68 Billion ≈ $392.41 Million |
-1.21% |
| 2014-12-31 | CN¥2.71 Billion ≈ $397.21 Million |
+4.89% |
| 2013-12-31 | CN¥2.59 Billion ≈ $378.69 Million |
+3.37% |
| 2012-12-31 | CN¥2.50 Billion ≈ $366.34 Million |
+4.13% |
| 2011-12-31 | CN¥2.40 Billion ≈ $351.82 Million |
+8.83% |
| 2010-12-31 | CN¥2.21 Billion ≈ $323.29 Million |
+326.48% |
| 2009-12-31 | CN¥518.02 Million ≈ $75.80 Million |
+32.79% |
| 2008-12-31 | CN¥390.10 Million ≈ $57.08 Million |
+17.40% |
| 2007-12-31 | CN¥332.30 Million ≈ $48.63 Million |
-- |
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide… Read more